Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $49.1818.

Several analysts have recently issued reports on PHVS shares. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Royal Bank Of Canada dropped their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. UBS Group set a $74.00 price objective on Pharvaris in a research note on Wednesday, May 13th. Finally, Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company.

Pharvaris Stock Performance

NASDAQ PHVS opened at $32.80 on Friday. The stock’s 50 day moving average is $30.02 and its 200 day moving average is $27.74. Pharvaris has a 12 month low of $16.72 and a 12 month high of $34.41. The stock has a market cap of $2.15 billion, a PE ratio of -10.31 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts forecast that Pharvaris will post -3.22 EPS for the current fiscal year.

Insider Transactions at Pharvaris

In related news, Director Robert Glassman sold 10,000 shares of Pharvaris stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.82, for a total transaction of $298,200.00. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at approximately $313,110. This trade represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the completion of the sale, the director directly owned 355,167 shares in the company, valued at approximately $10,768,663.44. The trade was a 7.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 214,909 shares of company stock valued at $6,421,745. 11.84% of the stock is owned by company insiders.

Institutional Trading of Pharvaris

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. Legal & General Group Plc boosted its stake in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the last quarter. Amundi boosted its stake in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after buying an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after buying an additional 7,879 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.